XE9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Settlement Boosts Near-term Cash RunwayThe $105M settlement converts uncertain U.S. royalty receipts into near-term, non-dilutive cash received in two installments and management says it restores operating runway through 2028. This materially reduces near-term financing pressure and supports funding of planned clinical milestones and R&D execution over the multi-year horizon.
Low Leverage Provides Balance-sheet FlexibilityRelatively low debt and a reduced debt-to-equity ratio give the company flexibility to fund ongoing R&D via cash, partnerships, or selective financing without onerous interest burdens. For a clinical-stage biotech this lowers refinancing risk and helps preserve strategic optionality while clinical programs de-risk over the next 2–3 years.
Proprietary XmAb Platform And TL1A PipelineXencor's antibody-engineering platform (XmAb, Xtend Fc) and advancing TL1A autoimmune/IBD candidates create durable competitive advantages. Platform-derived molecules and multiple upcoming clinical readouts through 2026–2027 support the potential for differentiated, longer-acting biologics and provide multiple value-inflection points if clinical data validate superiority in a multibillion-dollar IBD market.
Bears Say
High Cash BurnSustained, large negative operating and free cash flows indicate the company is consuming cash materially to fund R&D and operations. Continued burn elevates financing risk, potentially forcing dilutive equity raises or onerous deals if clinical progress stalls, and means runway improvements (like the settlement) are critical but not a permanent fix absent durable cash generation.
Declining Revenue With Deep Net LossesA meaningful decline in TTM revenue paired with very large negative net margins shows the business has not yet translated R&D into scalable product revenues. Persistent operating losses pressure returns, reduce reinvestment capacity, and make long-term viability dependent on successful clinical outcomes, milestone timing, or additional financing.
Loss Of Future U.S. Ultomiris Royalties Reduces Recurring RevenueTrading future U.S. royalties for a lump-sum settlement reduces predictable, long-term royalty cash flow. While ex-U.S. royalties remain, the elimination of the U.S. stream lessens future recurring revenue diversification and increases reliance on the pipeline and partnerships to generate sustainable, repeatable revenue beyond the near-term cash benefit.
Xencor News
XE9 FAQ
What was Xencor Inc’s price range in the past 12 months?
Currently, no data Available
What is Xencor Inc’s market cap?
Xencor Inc’s market cap is CHF1.17B.
When is Xencor Inc’s upcoming earnings report date?
Xencor Inc’s upcoming earnings report date is Aug 05, 2026 which is in 5 days.
How were Xencor Inc’s earnings last quarter?
Xencor Inc released its earnings results on May 06, 2026. The company reported -CHF1.379 earnings per share for the quarter, missing the consensus estimate of -CHF0.669 by -CHF0.71.
Is Xencor Inc overvalued?
According to Wall Street analysts Xencor Inc’s price is currently Undervalued.
Does Xencor Inc pay dividends?
Xencor Inc does not currently pay dividends.
What is Xencor Inc’s EPS estimate?
Xencor Inc’s EPS estimate is -0.65.
How many shares outstanding does Xencor Inc have?
Currently, no data Available
What happened to Xencor Inc’s price movement after its last earnings report?
Xencor Inc reported an EPS of -CHF1.379 in its last earnings report, missing expectations of -CHF0.669. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Xencor Inc?
Currently, no hedge funds are holding shares in CH:XE9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF19.38 (― Upside)
CHF19.38 (― Upside)
Blogger Sentiment
Bullish
CH:XE9 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.55%
Trailing 12-Months
Company Description
Xencor Inc
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XE9 Stock 12 Month Forecast
Average Price Target
―CytomX Therapeutics
―
AnaptysBio
―
Zymeworks
―
AbCellera Biologics
―
Inhibrx Biosciences Inc
―